JP2001247481A - Medicinal composition - Google Patents
Medicinal compositionInfo
- Publication number
- JP2001247481A JP2001247481A JP2000060560A JP2000060560A JP2001247481A JP 2001247481 A JP2001247481 A JP 2001247481A JP 2000060560 A JP2000060560 A JP 2000060560A JP 2000060560 A JP2000060560 A JP 2000060560A JP 2001247481 A JP2001247481 A JP 2001247481A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- pharmaceutical composition
- rhinitis
- nasal
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 32
- 206010039083 rhinitis Diseases 0.000 claims abstract description 19
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 10
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims abstract description 9
- 201000009151 chronic rhinitis Diseases 0.000 claims abstract description 9
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 19
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 11
- -1 S-2474 Chemical compound 0.000 claims description 8
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 8
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 5
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims description 5
- 239000000043 antiallergic agent Substances 0.000 claims description 5
- 229940124623 antihistamine drug Drugs 0.000 claims description 5
- 229960004958 ketotifen Drugs 0.000 claims description 5
- 229960005042 mequitazine Drugs 0.000 claims description 5
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims description 5
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 claims description 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 4
- JHBIMJKLBUMNAU-UHFFFAOYSA-N SC-58125 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 JHBIMJKLBUMNAU-UHFFFAOYSA-N 0.000 claims description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 4
- 229960000590 celecoxib Drugs 0.000 claims description 4
- 229960001929 meloxicam Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims description 4
- 229960000965 nimesulide Drugs 0.000 claims description 4
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 4
- 229960000371 rofecoxib Drugs 0.000 claims description 4
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims description 3
- 229960000428 carbinoxamine Drugs 0.000 claims description 3
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 3
- 229960003291 chlorphenamine Drugs 0.000 claims description 3
- 229960003449 epinastine Drugs 0.000 claims description 3
- 229950003909 iguratimod Drugs 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 5
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 5
- 230000001387 anti-histamine Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 206010028748 Nasal obstruction Diseases 0.000 abstract description 3
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 206010028735 Nasal congestion Diseases 0.000 description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- 229960001948 caffeine Drugs 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 201000009240 nasopharyngitis Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940111134 coxibs Drugs 0.000 description 5
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229960002548 epinastine hydrochloride Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 230000010352 nasal breathing Effects 0.000 description 5
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- JJAPPCJXQFKMJL-UHFFFAOYSA-N 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-methylsulfinylphenyl)pyrazole Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(=CC=2)S(C)=O)=CC(C(F)F)=N1 JJAPPCJXQFKMJL-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 3
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010028741 Nasal inflammation Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101150042515 DA26 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HFBYLYCMISIEMM-FFHNEAJVSA-N dihydrocodeine phosphate Chemical compound OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC HFBYLYCMISIEMM-FFHNEAJVSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、感冒やアレルギー
性鼻炎によって起こる慢性的な鼻炎症状における鼻閉に
対する効果が増強され、かつ長期間に渡り服用可能な医
薬組成物に関する。The present invention relates to a pharmaceutical composition which has an enhanced effect on nasal congestion in chronic rhinitis symptoms caused by cold and allergic rhinitis and can be taken for a long period of time.
【０００２】[0002]
【従来の技術】従来より多種の感冒やアレルギー性鼻炎
の鼻炎用組成物が知られているが、何れも風邪などに伴
う鼻粘膜の炎症症状に対する効果が充分でなかった。ま
た、効果を高めるために抗炎症作用のある非選択的シク
ロオキシゲナーゼ阻害非ステロイド性抗炎症薬と組み合
わせた場合、胃への障害が起こり長期間服用することが
不可能であった。2. Description of the Related Art Various types of rhinitis compositions for colds and allergic rhinitis have been known, but none of them has a sufficient effect on inflammatory symptoms of the nasal mucosa caused by colds and the like. In addition, when combined with a non-selective cyclooxygenase-inhibiting non-steroidal anti-inflammatory drug having an anti-inflammatory action to enhance the effect, the stomach is damaged and it is impossible to take it for a long time.
【０００３】感冒はウイルス性の呼吸器感染症であり、
一般に、上気道を中心とする局所炎症性症状に倦怠感等
の種々の全身症状を伴う疾患である。感冒の原因となる
ウイルスに対し、ウイルスの感染及び増殖を抑制させる
抗ウイルス作用を有する薬剤の開発が原因療法として望
まれるが、現時点の技術水準では依然として有効なもの
が開発される状況になく、個々の風邪症状の改善を目的
とする対症療法が感冒の中心となっている。[0003] Cold is a viral respiratory infection,
Generally, it is a disease accompanied by various systemic symptoms such as malaise and local inflammatory symptoms mainly in the upper respiratory tract. For the virus that causes the common cold, the development of a drug having an antiviral effect that suppresses the infection and proliferation of the virus is desired as a causative therapy, but at the current state of the art, there is no situation where an effective drug is still being developed. Symptomatic treatment aimed at improving individual cold symptoms is central to colds.
【０００４】対症療法は解熱鎮痛薬成分による発熱時の
解熱及び疼痛症状発症時の鎮痛であるが、感冒時などに
は選択的シクロオキシゲナーゼ−２阻害非ステロイド性
抗炎症薬は従来あまり用いられてはおらず、用いられる
ことがあっても単味剤としての使用であった。しかし、
感冒及び鼻炎は罹患の際に同時に種々の症状を併発し推
移することから、多岐にわたる症状の早期治療を図る必
要がある。さらに、最近の感冒では症状が長期化する傾
向にあり、特に鼻炎や咳などの症状は特にその傾向にあ
る。そこで、その症状を改善するために長期に渡り薬物
を使用するために、薬物の副作用の発生を防止するとい
う点で効果の増強により配合量を軽減した配合剤や副作
用発生率の少ない成分を配合した配合剤の開発が望まれ
ており、如何にこのような目的を達する処方を組むかが
ポイントとなっていた。[0004] Symptomatic treatment is antipyretic due to antipyretic analgesic components and analgesia at the onset of pain symptoms. At the time of common cold, etc., selective cyclooxygenase-2 inhibiting nonsteroidal anti-inflammatory drugs have not been widely used. In some cases, it was used as a simple agent even if used. But,
Since cold and rhinitis are accompanied by various symptoms at the same time when they are affected, it is necessary to treat various symptoms at an early stage. In addition, recent colds tend to have prolonged symptoms, particularly symptoms such as rhinitis and cough. Therefore, in order to use the drug over a long period of time to improve its symptoms, a combination drug with a reduced compounding amount and a component with a low incidence of side effects are added by enhancing the effect in terms of preventing the occurrence of side effects of the drug in order to prevent the occurrence of side effects of the drug It has been desired to develop such a compounding agent, and how to formulate such a purpose has been a key point.
【０００５】一方、従来の慢性鼻炎用組成物は抗ヒスタ
ミン薬を主とし、これに加えて鼻汁分泌抑制薬や鼻閉除
去を目的とした交感神経興奮薬等を配合したものが中心
となっており、さらに呼吸器粘膜の炎症除去を目的とし
た非選択的シクロオキシゲナーゼ阻害非ステロイド性抗
炎症薬を配合したものは存在するが、慢性的な鼻炎に対
して長期間使用することにより、胃障害等の副作用が懸
念された。On the other hand, conventional compositions for chronic rhinitis mainly contain antihistamines, and in addition to these, a composition containing a nasal secretion inhibitor, a sympathomimetic for removing nasal congestion, and the like. In addition, there are some that contain non-selective cyclooxygenase-inhibiting non-steroidal anti-inflammatory drugs for the purpose of removing inflammation of respiratory mucosa. Side effects were a concern.
【０００６】特に日常生活を営む上で、感冒やアレルギ
ー性による鼻炎症状、殊に鼻閉症状は呼吸不全を来た
し、物事に対する集中力を散漫なものにさせ、甚だしい
場合は不測の事態の発生を惹起する危険性を有する。そ
ればかりでなく、感冒の場合、口による呼吸を行うこと
による外気の直接の肺への取り込みは新たなウイルスや
細菌の感染に結びつくために症状の遷延化を招く不都合
を生じる。以上のことから慢性的な鼻閉状態に対して、
如何に効果的に鼻閉症状状態を除去し、また、慢性的な
症状に対して長期的に服用できるような薬剤による治療
が重要なポイントとなっている。Particularly in daily life, rhinitis due to colds and allergies, especially nasal congestion, causes respiratory failure and distracts the ability to concentrate on things. In extreme cases, unexpected situations may occur. There is a risk of causing. In addition, in the case of the common cold, the direct uptake of fresh air into the lungs by breathing through the mouth leads to new viral and bacterial infections, leading to the disadvantage of prolonged symptoms. From the above, for chronic nasal congestion,
An important point is how to effectively eliminate nasal congestion and to treat chronic symptoms with a drug that can be taken for a long period of time.
【０００７】[0007]
【発明が解決しようとする課題】本発明は上述の従来技
術に鑑みてなされるものであり、その目的は感冒による
慢性的鼻炎症状や、慢性的なアレルギー性鼻炎等の鼻炎
に対して有効な医薬組成物、特に長期的な使用が可能
で、鼻閉の除去あるいは軽減に有効な医薬組成物を提供
することにある。SUMMARY OF THE INVENTION The present invention has been made in view of the above-mentioned prior art, and has as its object to be effective against chronic rhinitis caused by cold and rhinitis such as chronic allergic rhinitis. It is an object of the present invention to provide a pharmaceutical composition, particularly a pharmaceutical composition which can be used for a long time and is effective for removing or reducing nasal congestion.
【０００８】[0008]
【課題を解決するための手段】本発明者らは、上記課題
を解決すべく、急性的な鼻炎のメディエーターであるプ
ロスタグランジンＥ２はシクロオキシゲナーゼ−１を介
して合成されるが、慢性的な鼻炎のメディエーターであ
るプロスタグランジンＥ２はシクロオキシゲナーゼ−２
を介して合成されることに着目し、研究を行った。そし
て、選択的シクロオキシゲナーゼ−２阻害非ステロイド
性抗炎症薬と抗アレルギー薬ないし抗ヒスタミン薬を配
合することにより、鼻粘膜の炎症症状（鼻閉など）の除
去あるいは軽減に対し劇的な効果があること、また本組
成物を長期的に使用しても胃障害等の副作用が非選択的
シクロオキシゲナーゼ阻害非ステロイド性抗炎症薬を配
合した組成物より低いことを見いだし、本発明を完成し
た。Means for Solving the Problems In order to solve the above problems, the present inventors have proposed that prostaglandin E2, a mediator of acute rhinitis, is synthesized via cyclooxygenase-1, but chronic rhinitis. Mediator prostaglandin E2 is cyclooxygenase-2
The research focused on being synthesized via By combining a selective cyclooxygenase-2 inhibiting non-steroidal anti-inflammatory drug with an anti-allergic or anti-histamine drug, it has a dramatic effect on the elimination or reduction of inflammatory symptoms (such as nasal congestion) of the nasal mucosa. In addition, the present inventors have found that, even when the composition is used for a long period of time, side effects such as gastric damage are lower than those of a composition containing a non-selective cyclooxygenase-inhibiting nonsteroidal anti-inflammatory drug.
【０００９】すなわち、本発明は、次の成分（ａ）およ
び（ｂ）（ａ）選択的シクロオキシゲナーゼ−２阻害非
ステロイド性抗炎症薬、（ｂ）抗アレルギーないし抗ヒ
スタミン薬を配合してなる医薬組成物を提供するもので
ある。That is, the present invention provides a pharmaceutical composition comprising the following components (a) and (b), (a) a selective cyclooxygenase-2 inhibiting nonsteroidal anti-inflammatory drug, and (b) an antiallergic or antihistamine drug. It provides a composition.
【００１０】本発明はまた、鼻炎治療ないし改善用薬剤
である前記医薬組成物を提供するものである。[0010] The present invention also provides the above pharmaceutical composition which is a drug for treating or improving rhinitis.
【００１１】更に本発明は、慢性的な鼻炎の治療ないし
改善用薬剤である前記医薬組成物を提供するものであ
る。Further, the present invention provides the above-mentioned pharmaceutical composition which is a drug for treating or improving chronic rhinitis.
【００１２】[0012]
【発明の実施の形態】本発明の医薬組成物は、上記の選
択的シクロオキシゲナーゼ−２阻害非ステロイド性抗炎
症薬（成分（ａ））と、抗アレルギーないし抗ヒスタミ
ン薬（成分（ｂ））を常法に従って配合し、製剤化する
ことにより調製される。BEST MODE FOR CARRYING OUT THE INVENTION The pharmaceutical composition of the present invention comprises the above-mentioned selective cyclooxygenase-2 inhibiting nonsteroidal anti-inflammatory drug (component (a)) and an antiallergic or antihistamine drug (component (b)). It is prepared by blending and formulating according to a conventional method.
【００１３】成分（ａ）である選択的シクロオキシゲナ
ーゼ−２阻害非ステロイド性抗炎症薬（以下、「ＣＯＸ
−２阻害剤」という）としては、メロキシカム、Ｔ−６
１４（３−ホルミルアミノ−７−メチルスルホニルアミ
ノ−６−フェノキシ−４Ｈ−１−ベンゾピラン−４−オ
ン）、セレコキシブ、ＪＴＥ−５２２（４−（４−シク
ロヘキシル−２−メチルオキサゾール−５−イル）−２
−フルオロベンゼンスルホンアミド）、ニメスリド、Ｓ
−２４７４（５（Ｅ）−（３,５−ジ−ｔｅｒｔ.−ブチ
ル−４−ヒドロキシ）ベンジリデン−２−エチル−１,
２−イソチアゾリジン−１,１−ジオキシド）、ＳＣ−
５８１２５（５−（４−フルオロフェニル）−１−［４
−（メチルスルホニル）フェニル］−３−（トリフルオ
ロメチル）−１Ｈ−ピラゾール）、ＦＲ−１４０４２３
（３−（ジフルオロメチル）−１−（４−メトキシフェ
ニル）−５−［４−（メチルスルフィニル）フェニル］
ピラゾール）、ロフェコキシブ及びこれらの塩類が挙げ
られる。塩類の例としては、塩酸塩、硝酸塩、硫酸塩、
リン酸塩、シュウ酸塩、マレイン酸塩、フマル酸塩、臭
化水素酸塩などが挙げられる。Component (a), a selective cyclooxygenase-2 inhibiting nonsteroidal anti-inflammatory drug (hereinafter referred to as "COX
-2 inhibitor)) as meloxicam, T-6
14 (3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one), celecoxib, JTE-522 (4- (4-cyclohexyl-2-methyloxazol-5-yl) -2
-Fluorobenzenesulfonamide), nimesulide, S
-2474 (5 (E)-(3,5-di-tert.-butyl-4-hydroxy) benzylidene-2-ethyl-1,
2-isothiazolidine-1,1-dioxide), SC-
58125 (5- (4-fluorophenyl) -1- [4
-(Methylsulfonyl) phenyl] -3- (trifluoromethyl) -1H-pyrazole), FR-140423
(3- (difluoromethyl) -1- (4-methoxyphenyl) -5- [4- (methylsulfinyl) phenyl]
Pyrazole), rofecoxib and salts thereof. Examples of salts include hydrochloride, nitrate, sulfate,
Phosphate, oxalate, maleate, fumarate, hydrobromide and the like can be mentioned.
【００１４】上記の各ＣＯＸ−２阻害剤は、何れも公知
化合物であり、例えば「医薬ジャーナル」、第３５巻、
Ｓ−１、（１９９９）の第１３６頁から第１４０頁に詳
しく記載されている。Each of the above-mentioned COX-2 inhibitors is a known compound, and is described in, for example, "Pharmaceutical Journal", Vol.
S-1, (1999), pp. 136-140.
【００１５】また、成分（ｂ）である抗アレルギーない
し抗ヒスタミン薬としては、メキタジン、ケトチフェ
ン、エピナスチン、クロルフェニラミン、カルビノキサ
ミン及びこれらの塩類が挙げられる。塩類としては上記
した塩が例示される。The antiallergic or antihistamine as the component (b) includes mequitazine, ketotifen, epinastine, chlorpheniramine, carbinoxamine and salts thereof. Examples of the salts include the salts described above.
【００１６】本発明の医薬組成物の調製に当たっての、
ＣＯＸ−２阻害剤と抗アレルギー薬ないし抗ヒスタミン
薬との配合比は、ＣＯＸ−２阻害剤１重量部に対して抗
アレルギー薬ないし抗ヒスタミン薬は０.００１〜２重
量部程度とすることが好ましい。In preparing the pharmaceutical composition of the present invention,
The mixing ratio of the COX-2 inhibitor to the antiallergic or antihistamine should be about 0.001 to 2 parts by weight of the antiallergic or antihistamine per 1 part by weight of the COX-2 inhibitor. preferable.
【００１７】また、各成分の配合量は、それぞれの薬剤
毎に、薬効強度や安全性を考慮して定める必要がある。
例えば、成分（ａ）であるＣＯＸ−２阻害剤のうち、メ
ロキシカム（その塩を含む）は、成人に対して１日当た
り２.５ｍｇ〜３０ｍｇ、Ｔ−６１４（その塩を含む）
は５ｍｇ〜５０ｍｇ、セレコキシブ（その塩を含む）は
５ｍｇ〜２００ｍｇ、ＪＴＥ−５２２（その塩を含む）
は１ｍｇ〜２００ｍｇ、ニメスリド（その塩を含む）は
１０ｍｇ〜３００ｍｇ、Ｓ−２４７４（その塩を含む）
は１ｍｇ〜４００ｍｇ、ＳＣ−５８１２５（その塩を含
む）は１ｍｇ〜２００ｍｇ、ＦＲ−１４０４２３（その
塩を含む）は１ｍｇ〜２００ｍｇ、ＮＳ−３９８は１ｍ
ｇ〜２００ｍｇ、ロフェコキシブは５ｍｇ〜１２５ｍｇ
程度を配合することがそれぞれ好ましい。The amount of each component must be determined for each drug in consideration of the efficacy and safety.
For example, among the COX-2 inhibitors that are component (a), meloxicam (including its salt) is 2.5 mg to 30 mg per day for adults, and T-614 (including its salt) for adults.
Is 5 mg to 50 mg, celecoxib (including its salt) is 5 mg to 200 mg, JTE-522 (including its salt)
1 mg to 200 mg, Nimesulide (including its salt) 10 mg to 300 mg, S-2474 (including its salt)
Is 1 mg to 400 mg, SC-58125 (including its salt) is 1 mg to 200 mg, FR-140423 (including its salt) is 1 mg to 200 mg, and NS-398 is 1 m.
g-200mg, rofecoxib 5mg-125mg
It is preferable to mix the degrees.
【００１８】一方、成分（ｂ）である抗アレルギー薬な
いし抗ヒスタミン薬の配合量としては、例えば、メキタ
ジンは２〜１２ｍｇ、ケトチフェン又はその塩類は０.
５〜３ｍｇ、エピナスチン（その塩を含む）は５〜２０
ｍｇ、クロルフェニラミン又はその塩類は２〜１０ｍ
ｇ、カルビノキサミン又はその塩類は５〜２０ｍｇ程度
がそれぞれ好ましい。On the other hand, the compounding amount of the antiallergic or antihistamine, which is the component (b), is, for example, 2 to 12 mg for mequitazine and 0.1 for ketotifen or its salts.
5 to 3 mg, epinastine (including its salt) 5 to 20
mg, chlorpheniramine or a salt thereof is 2 to 10 m
g, carbinoxamine or a salt thereof is preferably about 5 to 20 mg.
【００１９】本発明の医薬組成物は、上記成分（ａ）の
１種またはそれ以上と、成分（ｂ）の１種またはそれ以
上組み合わせて配合し、錠剤、カプセル剤、顆粒剤、細
粒剤、粉剤、チュアブル剤、発泡剤、ドロップ剤、口中
溶解剤、ドライシロップ剤、内服液剤などの経口投与形
態の製剤とされる。The pharmaceutical composition of the present invention is prepared by combining one or more of the above-mentioned components (a) and one or more of the above-mentioned components (b) in combination, and comprises tablets, capsules, granules and fine granules. And oral dosage forms such as powders, chewables, foaming agents, drops, mouth solubilizers, dry syrups, and oral liquids.
【００２０】これらの製剤は、常法により調製すること
ができる。固形剤において製剤の調製に使用する担体と
しては、乳糖、デンプン、砂糖、マンニトール、結晶セ
ルロースなどの賦形剤、ヒドロキシプロピルセルロー
ス、ヒドロキシプロピルメチルセルロース、ゼラチン、
ＰＶＰなどの結合剤、カルボキシメチルセルロースカル
シウム、低置換度ヒドロキシプロピルセルロースなどの
崩壊剤、ステアリン酸マグネシウム、硬化ヒマシ油、タ
ルクなどの滑沢剤などを例示することができ、この他必
要に応じて溶解補助剤、緩衝剤、保存剤、香料、色素、
矯味剤などを使用することができる。These preparations can be prepared by a conventional method. Carriers used in the preparation of solid preparations include lactose, starch, sugar, mannitol, excipients such as crystalline cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin,
Examples include binders such as PVP, disintegrants such as carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, and lubricating agents such as magnesium stearate, hydrogenated castor oil, and talc. Auxiliaries, buffers, preservatives, fragrances, dyes,
Flavoring agents and the like can be used.
【００２１】また、内服液剤において製剤の調製に使用
する担体としては、ショ糖脂肪酸エステル類、ステアリ
ン酸ポリオキシル類、ポリオキシエチレンポリオキシプ
ロピレングリコール類、ポリオキシエチレンモノ脂肪酸
エステル類などの界面活性剤、合成ケイ酸アルミニウ
ム、ケイ酸マグネシウム、炭酸マグネシウム、酸化マグ
ネシウム、メタケイ酸アルミン酸マグネシウムなどの増
粘剤、クエン酸緩衝液、リン酸緩衝液などの有機酸系・
無機酸系のｐＨ調整剤などを例示することができ、この
他必要に応じて溶解補助剤、緩衝剤、保存剤、香料、色
素、甘味剤などを使用することができる。Carriers used in the preparation of preparations for internal liquids include surfactants such as sucrose fatty acid esters, polyoxyl stearate, polyoxyethylene polyoxypropylene glycols and polyoxyethylene monofatty acid esters. Thickeners such as synthetic aluminum silicate, magnesium silicate, magnesium carbonate, magnesium oxide, magnesium metasilicate, and organic acids such as citrate buffer and phosphate buffer.
Inorganic acid-based pH adjusters and the like can be exemplified. In addition, if necessary, a solubilizing agent, a buffer, a preservative, a flavor, a pigment, a sweetener and the like can be used.
【００２２】本発明の医薬組成物は、以上の成分の他に
必要に応じて他の非ステロイド性抗炎症薬、消炎酵素薬
類、気管支拡張薬、中枢神経興奮薬、鎮咳薬、去痰薬、
他の抗ヒスタミン薬又は抗コリン薬、ビタミン類、制酸
薬、生薬などから選ばれる少なくとも１つの薬剤を適宜
に配合しても良い。なお、これらの成分は単独又は相互
に混合して用いることができ、通常は医薬品製造指針
（１９９５年版・薬業時報社）に収載されているかぜ薬
基準などに準拠して配合される。The pharmaceutical composition of the present invention may further contain, if necessary, other nonsteroidal anti-inflammatory drugs, anti-inflammatory enzymes, bronchodilators, central nervous stimulants, antitussives, expectorants,
At least one drug selected from other antihistamines or anticholinergics, vitamins, antacids, crude drugs, and the like may be appropriately compounded. These components can be used alone or as a mixture with each other. Usually, these components are blended in accordance with the standard for cold medicine described in the Pharmaceutical Manufacturing Guideline (1995 edition of Pharmaceutical Times).
【００２３】かくして得られる本発明の医薬組成物は、
通常、成人に対して１日１回ないし数回に分けて経口投
与することができる。この投与量は年齢、体重、病状に
より適宜増減することができる。The pharmaceutical composition of the present invention thus obtained is
Usually, it can be orally administered to an adult once or several times a day. This dose can be appropriately adjusted depending on the age, weight, and medical condition.
【００２４】[0024]
【発明の効果】本発明の医薬組成物は、慢性の鼻粘膜の
炎症に対する消炎効果が増強・改善するため、鼻炎症状
の軽減・除去に対して劇的な効果を有するものである。
従って、本発明の医薬組成物は、感冒、特に感冒が長引
いたために起こる慢性鼻炎の鼻閉、又はアレルギー性鼻
炎の鼻閉に対して、著しく有用な薬剤である。The pharmaceutical composition of the present invention has a dramatic effect on the reduction and elimination of nasal inflammation because the anti-inflammatory effect on chronic nasal mucosal inflammation is enhanced and improved.
Therefore, the pharmaceutical composition of the present invention is a remarkably useful drug for common cold, especially for nasal congestion of chronic rhinitis or allergic rhinitis caused by prolonged cold.
【００２５】[0025]
【実施例】以下、実施例及び試験例を挙げ本発明をさら
に詳しく説明するが、本発明はこれら実施例等に何ら制
約されるものではない。The present invention will be described in more detail with reference to examples and test examples, but the present invention is not limited to these examples.
【００２６】実 施 例 １ 下記の各成分をそれぞれ秤量し均一に混合した後、得ら
れた混合粉末を直打法により１錠重量２６０ｍｇになる
ように打錠し錠剤を得た。Example 1 The following components were weighed and uniformly mixed, and the resulting mixed powder was tableted by a direct compression method to a tablet weight of 260 mg to obtain tablets.
【００２７】（ 処 方 ） ロフェコキシブ ５０ｇ メキタジン ６ｇ リン酸ジヒドロコデイン ２４ｇ ｄｌ−塩酸メチルエフェドリン ６０ｇ ノスカピン ４８ｇ 塩酸ブロムヘキシン １２ｇ 塩酸フェニルプロパノールアミン ６０ｇ 塩化リゾチーム ９０ｇ 無水カフェイン ７５ｇ ビタミンＢ１硝酸塩 ８ｇ ビタミンＢ２ ４ｇ 乳 糖 ８１３ｇ 微結晶セルロース ３１５ｇ ヒドロキシプロピルセルロース １０５ｇ 低置換度ヒドロキシプロピルセルロース ４００ｇ ステアリン酸マグネシウム １０ｇ[0027] (prescription) rofecoxib 50g mequitazine 6g phosphate dihydrocodeine 24 g dl-methylephedrine hydrochloride ephedrine 60g noscapine 48g bromhexine hydrochloride 12g of phenylpropanolamine hydrochloride 60g lysozyme chloride 90g anhydrous caffeine 75g Vitamin B 1 nitrate 8g vitamin B 2 4g Lactose 813g Microcrystalline cellulose 315 g Hydroxypropyl cellulose 105 g Low substituted hydroxypropyl cellulose 400 g Magnesium stearate 10 g
【００２８】実 施 例 ２ 下記の成分をそれぞれ秤量し均一に混合した後、実施例
１に準拠し１錠重量３００ｍｇの錠剤を得た。Example 2 The following components were weighed and uniformly mixed, and a tablet weighing 300 mg per tablet was obtained in accordance with Example 1.
【００２９】（ 処 方 ） メロキシカム ５ｇ 塩酸エピナスチン １０ｇ 塩酸フェニルプロパノールアミン ６０ｇ 塩化リゾチーム ９０ｇ 乳 糖 ３５０ｇ 結晶セルロース ２４５ｇ ＣＭＣ−カルシウム ５０ｇ ヒドロキシプロピルセルロース ８０ｇ ステアリン酸マグネシウム １０ｇ(Preparation) Meloxicam 5 g Epinastine hydrochloride 10 g Phenylpropanolamine hydrochloride 60 g Lysozyme chloride 90 g Lactose 350 g Crystalline cellulose 245 g CMC-calcium 50 g Hydroxypropyl cellulose 80 g Magnesium stearate 10 g
【００３０】実 施 例 ３ 下記の成分をそれぞれ秤量し均一に混合した後、実施例
１に準拠し１錠重量１８０ｇの錠剤を得た。Example 3 After weighing and uniformly mixing the following components, a tablet weighing 180 g was obtained according to Example 1.
【００３１】（ 処 方 ） Ｔ−６１４ ４０ｇ ケトチフェン ２ｇ 塩酸フェニルプロパノールアミン ６０ｇ 無水カフェイン ７５ｇ 結晶セルロース １０３ｇ 低置換度ヒドロキシプロピルセルロース ５０ｇ ヒドロキシプロピルセルロース ２５ｇ タルク ５ｇ(Preparation) T-614 40 g Ketotifen 2 g Phenylpropanolamine hydrochloride 60 g Anhydrous caffeine 75 g Crystalline cellulose 103 g Low-substituted hydroxypropylcellulose 50 g Hydroxypropylcellulose 25 g Talc 5 g
【００３２】実 施 例 ４ 下記の成分をそれぞれ秤量し均一に混合した後、精製水
を噴霧しながら撹拌造粒機にて造粒し、乾燥機にて乾燥
し、１回服用量８５０ｍｇの顆粒剤を得た。Example 4 The following components were weighed and mixed uniformly, and then granulated with a stirring granulator while spraying purified water, dried with a dryer, and granulated in a single dose of 850 mg. Agent was obtained.
【００３３】（ 処 方 ） セレコキシブ ５０ｇ メキタジン ６ｇ 塩酸フェニレフリン ３０ｇ バレイショデンプン ５１４ｇ マンニトール ２００ｇ ヒドロキシプロピルセルロース ５０ｇ(Preparation) Celecoxib 50 g Mequitadine 6 g Phenylephrine hydrochloride 30 g Potato starch 514 g Mannitol 200 g Hydroxypropyl cellulose 50 g
【００３４】実 施 例 ５ 下記の成分をそれぞれ秤量し均一に混合した後、精製水
を噴霧しながら撹拌造粒機にて造粒し、乾燥機にて乾燥
し、１回服用量１０００ｍｇの顆粒剤を得た。Example 5 The following components were individually weighed and uniformly mixed, and then granulated with a stirring granulator while spraying purified water, dried with a dryer, and granulated in a single dose of 1000 mg. Agent was obtained.
【００３５】（ 処 方 ） ＪＴＥ−５２２ １０ｇ マレイン酸クロルフェニラミン １２ｇ 塩酸フェニレフリン ３０ｇ 無水カフェイン ７５ｇ バレイショデンプン ５５３ｇ ソルビトール ３００ｇ ヒドロキシプロピルセルロース ２０ｇ(Preparation) JTE-522 10 g Chlorpheniramine maleate 12 g Phenylephrine hydrochloride 30 g Anhydrous caffeine 75 g Potato starch 553 g Sorbitol 300 g Hydroxypropyl cellulose 20 g
【００３６】実 施 例 ６ 下記の成分をそれぞれ秤量し均一に混合した後、実施例
１に準拠し１錠重量２２５ｇの錠剤を得た。Example 6 The following components were weighed and uniformly mixed, and a tablet weighing 225 g was obtained according to Example 1.
【００３７】（ 処 方 ） ニメスリド １５ｇ マレイン酸カルビノキサミン １６ｇ 塩酸フェニルプロパノールアミン ６０ｇ 無水カフェイン ７５ｇ 微結晶セルロース １９８ｇ ＣＭＣ−ナトリウム ５０ｇ ヒドロキシプロピルセルロース ３６ｇ(Preparation) Nimesulide 15 g Carbinoxamine maleate 16 g Phenylpropanolamine hydrochloride 60 g Anhydrous caffeine 75 g Microcrystalline cellulose 198 g CMC-sodium 50 g Hydroxypropyl cellulose 36 g
【００３８】実 施 例 ７ 下記の成分をそれぞれ秤量し均一に混合した後、実施例
１に準拠し１錠重量１５０ｇの錠剤を得た。Example 7 The following components were weighed and uniformly mixed, and a tablet weighing 150 g was obtained according to Example 1.
【００３９】（ 処 方 ） Ｓ−２４７４ ５ｇ 塩酸エピナスチン １０ｇ 無水カフェイン ７５ｇ 乳 糖 １３０ｇ ＣＭＣ−カルシウム ６０ｇ ヒドロキシプロピルセルロース ２０ｇ(Preparation) S-2475 5 g Epinastine hydrochloride 10 g Anhydrous caffeine 75 g Lactose 130 g CMC-calcium 60 g Hydroxypropyl cellulose 20 g
【００４０】実 施 例 ８ ｐＨ調整剤（リン酸緩衝液）を溶解した水溶液に、防腐
剤、甘味剤、香料を加え完全に溶解させた。この溶液に
ショ糖脂肪酸エステルを均一に分散した後、ＳＣ−５８
１２５及びその他の薬剤を加え溶解させた後、精製水を
加えて全量を１０００ｍｌにして製した。Example 8 An antiseptic, a sweetener and a flavor were added to an aqueous solution in which a pH adjuster (phosphate buffer) was dissolved, and completely dissolved. After uniformly dispersing the sucrose fatty acid ester in this solution, SC-58
After 125 and other chemicals were added and dissolved, purified water was added to make the total volume 1000 ml.
【００４１】 （ 処 方 ） ＳＣ−５８１２５ １０ｇ メキタジン ６ｇ 塩酸フェニレフリン ３０ｇ 無水カフェイン ７５ｇ ショ糖脂肪酸エステル １５ｇ 甘味剤（ショ糖） 適 量 香 料 微 量 防腐剤（安息香酸ナトリウム） 適 量 ｐＨ調整剤 適 量 精製水 全量１０００ｍｌ(Preparation) SC-58125 10 g Mequitazine 6 g Phenylephrine hydrochloride 30 g Anhydrous caffeine 75 g Sucrose fatty acid ester 15 g Sweetener (sucrose) Appropriate amount Flavoring agent Fine amount Preservative (sodium benzoate) Appropriate amount pH adjuster Appropriate Volume Purified water Total volume 1000ml
【００４２】実 施 例 ９ ｐＨ調整剤（リン酸緩衝液）を溶解した水溶液に、防腐
剤、甘味剤、香料を加え完全に溶解させた。この溶液に
ショ糖脂肪酸エステルを均一に分散した後、ＦＲ−１４
０４２３及びその他の薬剤を加え溶解させた後、精製水
を加えて全量を１０００ｍｌにして製した。Example 9 An antiseptic, a sweetener and a flavor were added to an aqueous solution in which a pH adjuster (phosphate buffer) was dissolved, and completely dissolved. After uniformly dispersing the sucrose fatty acid ester in this solution, FR-14
After adding and dissolving 0423 and other chemicals, purified water was added to make a total volume of 1000 ml, thereby producing the product.
【００４３】 （ 処 方 ） ＦＲ−１４０４２３ １０ｇ ケトチフェン ２ｇ 塩酸フェニルプロパノールアミン ６０ｇ ショ糖脂肪酸エステル １５ｇ 甘味剤（ショ糖） 適 量 香 料 微 量 防腐剤（安息香酸ナトリウム） 適 量 ｐＨ調整剤 適 量 精製水 全量１０００ｍｌ(Preparation) FR-140423 10 g Ketotifen 2 g Phenylpropanolamine hydrochloride 60 g Sucrose fatty acid ester 15 g Sweetener (sucrose) qs Flavoring preservative (sodium benzoate) qs pH adjuster qs Purification 1000ml water
【００４４】試 験 例 ラット慢性鼻炎モデルに対する薬効の比較と胃障害比
較：下記に示す医薬組成物を調製し、それぞれについ
て、下記方法で鼻閉抑制効果およびび爛の発生を調べ
た。鼻閉抑制効果を図１に、び爛の発生を表１にそれぞ
れ示す。Test Example Comparison of drug efficacy and stomach disorder in rat chronic rhinitis model: The following pharmaceutical compositions were prepared, and for each of them, the nasal congestion inhibitory effect and the occurrence of sores were examined by the following methods. The effect of suppressing nasal congestion is shown in FIG. 1, and the occurrence of rash is shown in Table 1.
【００４５】（ 被験医薬および投与量 ） 本発明医薬： ロフェキシコブ ２５ｍｇ／ｋｇ 塩酸エピナスチン １０ｍｇ／ｋｇ 対照医薬１： 塩酸エピナスチン １０ｍｇ／ｋｇ 対照医薬２： アセチルサリチル酸 ３００ｍｇ／ｋｇ 塩酸エピナスチン １０ｍｇ／ｋｇ(Test Drug and Dosage) Drug of the present invention: Lofexicob 25 mg / kg Epinastine hydrochloride 10 mg / kg Control drug 1: Epinastine hydrochloride 10 mg / kg Control drug 2: Acetylsalicylic acid 300 mg / kg Epinastine hydrochloride 10 mg / kg
【００４６】（ 試 験 方 法 ） Ａ.鼻閉抑制試験：ハートレイ系雄性モルモットに卵白
アルブミン１０μｇ／ｋｇ及び水酸化アルミニウムゲル
５ｍｇ／ｋｇを２週間毎３回腹腔内投与したのち、局所
の感作のためネブライザーにて卵白アルブミン（３ｍｇ
／３ｍｌ）を３分間、４週間行い、能動感作モデルモル
モットを作製した。再度卵白アルブミンを点鼻し、３時
間後の鼻呼吸抵抗値を測定し、その直後に、上記投与量
となる量の本発明医薬または対照医薬の水溶液を投与し
た。その更に３０分後に、鼻呼吸抵抗値を測定した。モ
ルモットの鼻呼吸抵抗は、小動物用ボディプレチスモグ
ラムを用いてオッシレイション法により測定した。本発
明医薬群、対照医薬１群または対照医薬２群のいずれ
も、それぞれの群での医薬水溶液投与直前の鼻呼吸抵抗
値の値に対する投与後３０分後の鼻呼吸抵抗値の値を算
出し、これを百分率で示した。なお、上記試験ではそれ
ぞれ１群７匹とした。(Test Method) A. Nasal Constriction Inhibition Test: Hartley male guinea pigs were intraperitoneally administered with 10 μg / kg of ovalbumin and 5 mg / kg of aluminum hydroxide gel three times every two weeks for topical sensitization. Ovalbumin (3mg)
/ 3 ml) for 3 minutes for 4 weeks to prepare an active sensitized model guinea pig. Egg albumin was instilled again, and the nasal respiratory resistance was measured 3 hours later. Immediately thereafter, an aqueous solution of the medicament of the present invention or the control medicament of the above dose was administered. After another 30 minutes, the nasal respiratory resistance was measured. The nasal respiratory resistance of the guinea pig was measured by the oscillation method using a small animal body plethysmogram. In each of the medicament group of the present invention, the control medicine group 1 and the control medicine 2 group, the value of the nasal respiratory resistance value 30 minutes after administration relative to the value of the nasal respiratory resistance value immediately before administration of the aqueous pharmaceutical solution in each group was calculated. , Which are given as percentages. In the above test, each group consisted of 7 animals.
【００４７】Ｂ.び爛発生試験：絶食させたウイスター
系雄性ラット（１群７匹）に本発明医薬水溶液または対
照薬２を１日１回、１週間経口投与し、最終投与から４
時間後に動物を屠殺し、胃をホルマリンにて固定した
後、胃体部に発生したび爛の面積を実態顕微鏡下にて測
定した。本発明医薬または対照医薬２投与時のそれぞれ
のび爛の面積を表１に示した。B. Erosion Test: Male fasted Wistar rats (7 rats per group) were orally administered once daily for one week with the aqueous solution of the drug of the present invention or Control 2 and 4 weeks after the last administration.
After a lapse of time, the animals were sacrificed and the stomach was fixed with formalin, and then the area of the sores that had developed in the stomach body was measured under a stereoscopic microscope. Table 1 shows the area of each rash when the medicament of the present invention or the control drug 2 was administered.
【００４８】[0048]
【表１】 [Table 1]
【００４９】鼻呼吸の抵抗値と、鼻閉の度合いは相関が
高いと考えられるので、鼻呼吸の抵抗値を測ることによ
り鼻閉の度合いが測定できると判断される。図１の結果
から、組み合わせ処方群の方が単味群より鼻呼吸の抵抗
値が低く、鼻閉改善効果は組み合わせ処方に優れた効果
があることが示された。また、表１の結果からは、本発
明の医薬組成物では胃障害を発生しにくいことが示され
た。これらの結果から、本発明医薬組成物は、鼻炎に対
する医薬組成物として有用であることが明かとなった。Since the resistance value of nasal respiration and the degree of nasal obstruction are considered to have a high correlation, it is determined that the degree of nasal obstruction can be measured by measuring the nasal respiration resistance value. The results in FIG. 1 indicate that the combination prescription group had a lower nasal respiration resistance than the plain group, and the nasal congestion improving effect was superior to the combination prescription group. In addition, the results in Table 1 show that the pharmaceutical composition of the present invention hardly causes gastric damage. From these results, it became clear that the pharmaceutical composition of the present invention is useful as a pharmaceutical composition for rhinitis.
【図１】 被験医薬水溶液投与３０分後の鼻呼吸抵抗値
を、投与直前の鼻呼吸抵抗値に対する百分率として示し
た図面。 以 上FIG. 1 is a drawing showing the nasal respiration resistance 30 minutes after administration of a test drug aqueous solution as a percentage of the nasal respiration resistance immediately before administration. that's all
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｋ 31/4365 Ａ６１Ｋ 31/4365 31/4402 31/4402 31/5415 31/5415 31/55 31/55 31/635 31/635 Ａ６１Ｐ 11/02 Ａ６１Ｐ 11/02 (72)発明者 小友 進 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 Ｆターム(参考） 4C084 AA23 MA02 NA05 NA14 ZA591 ZB112 ZB132 ZC132 4C086 AA02 BA08 BC17 BC21 BC36 BC79 BC89 CB11 DA20 DA26 GA02 GA04 GA07 GA08 GA09 GA10 GA12 MA03 MA04 MA17 MA35 MA41 NA14 ZA59 ZB11 ZB13 ZC13 4C206 AA01 AA02 JA11 MA03 MA04 MA12 ZA59 ZB11 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 31/4365 A61K 31/4365 31/4402 31/4402 31/5415 31/5415 31/55 31/55 31 / 635 31/635 A61P 11/02 A61P 11/02 (72) Inventor Susumu Kotomo 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. F-term (reference) 4C084 AA23 MA02 NA05 NA14 ZA591 ZB112 ZB132 ZC132 4C086 AA02 BA08 BC17 BC21 BC36 BC79 BC89 CB11 DA20 DA26 GA02 GA04 GA07 GA08 GA09 GA10 GA12 MA03 MA04 MA17 MA35 MA41 NA14 ZA59 ZB11 ZB13 ZC13 4C206 AA01 AA02 JA11 MA03 MA04 MA12 ZA59 ZB11
Claims (5)
ド性抗炎症薬、 （ｂ）抗アレルギーないし抗ヒスタミン薬を配合してな
る医薬組成物。1. A pharmaceutical composition comprising the following components (a) and (b): (a) a selective cyclooxygenase-2 inhibiting nonsteroidal anti-inflammatory drug; and (b) an antiallergic or antihistamine drug.
ゼ−２阻害非ステロイド性抗炎症薬が、メロキシカム、
Ｔ−６１４、セレコキシブ、ＪＴＥ−５２２、ニメスリ
ド、Ｓ−２４７４、ＳＣ−５８１２５、ＦＲ−１４０４
２３、ロフェコキシブ及びこれらの塩類からなる群から
選ばれる薬剤の１種またはそれ以上である請求項第１項
記載の医薬組成物。2. The method of claim 1, wherein the selective cyclooxygenase-2 inhibiting nonsteroidal anti-inflammatory drug of component (a) is meloxicam,
T-614, celecoxib, JTE-522, nimesulide, S-2474, SC-58125, FR-1404
23. The pharmaceutical composition according to claim 1, which is one or more drugs selected from the group consisting of rofecoxib and salts thereof.
タミン薬が、メキタジン、ケトチフェン、エピナスチ
ン、クロルフェニラミン、カルビノキサミン及びこれら
の塩類からなる群から選ばれる薬剤の１種またはそれ以
上である請求項第１項記載の医薬組成物。3. The antiallergic or antihistamine drug of the component (b) is one or more drugs selected from the group consisting of mequitazine, ketotifen, epinastine, chlorpheniramine, carbinoxamine and salts thereof. The pharmaceutical composition according to claim 1.
第１項ないし第３項の何れかの項記載の医薬組成物。4. The pharmaceutical composition according to claim 1, which is a drug for treating or improving rhinitis.
ある請求項第１項ないし第４項の何れかの項記載の医薬
組成物。5. The pharmaceutical composition according to claim 1, which is a medicament for treating or ameliorating chronic rhinitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000060560A JP2001247481A (en) | 2000-03-06 | 2000-03-06 | Medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000060560A JP2001247481A (en) | 2000-03-06 | 2000-03-06 | Medicinal composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001247481A true JP2001247481A (en) | 2001-09-11 |
Family
ID=18580845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000060560A Withdrawn JP2001247481A (en) | 2000-03-06 | 2000-03-06 | Medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001247481A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004143162A (en) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | Nasal drip composition |
| JP2007530620A (en) * | 2004-04-01 | 2007-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Composition comprising meloxicam |
| JP2008501655A (en) * | 2004-06-04 | 2008-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Meloxicam-containing composition |
| JP2009513512A (en) * | 2003-07-09 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Composition comprising meloxicam |
| JP2010047566A (en) * | 2008-07-23 | 2010-03-04 | Takeda Chem Ind Ltd | Pharmaceutical composition |
| CN115703772A (en) * | 2021-08-09 | 2023-02-17 | 天地恒一制药股份有限公司 | Iguratimod eutectic crystal, and preparation method and application thereof |
-
2000
- 2000-03-06 JP JP2000060560A patent/JP2001247481A/en not_active Withdrawn
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004143162A (en) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | Nasal drip composition |
| JP4543274B2 (en) * | 2002-10-01 | 2010-09-15 | 大正製薬株式会社 | Nasal composition |
| JP2009513512A (en) * | 2003-07-09 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Composition comprising meloxicam |
| JP2012021025A (en) * | 2003-07-09 | 2012-02-02 | Boehringer Ingelheim Internatl Gmbh | Composition comprising meloxicam |
| JP2007530620A (en) * | 2004-04-01 | 2007-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Composition comprising meloxicam |
| JP2008501655A (en) * | 2004-06-04 | 2008-01-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Meloxicam-containing composition |
| JP2010047566A (en) * | 2008-07-23 | 2010-03-04 | Takeda Chem Ind Ltd | Pharmaceutical composition |
| CN115703772A (en) * | 2021-08-09 | 2023-02-17 | 天地恒一制药股份有限公司 | Iguratimod eutectic crystal, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4365107B2 (en) | Pharmaceutical composition | |
| JP5442178B2 (en) | Oral composition containing loxoprofen | |
| JP4365106B2 (en) | Pharmaceutical combination | |
| WO2005094832A1 (en) | Compositions comprising meloxicam | |
| JP2012021025A (en) | Composition comprising meloxicam | |
| JP2931409B2 (en) | Paracetamol and domperidone film-coated tablets | |
| JP2001199882A (en) | Composition for cold and rhinitis | |
| JP2006104186A (en) | Pharmaceutical composition for common cold | |
| JP5542309B2 (en) | Oral pharmaceutical composition | |
| JP5828609B2 (en) | Persistent antipyretic analgesic anti-inflammatory agent | |
| JP3122748B2 (en) | Antipyretic analgesic containing ibuprofen | |
| JP2012051949A (en) | Loxoprofen-containing composition 2 for oral administration | |
| JP3170855B2 (en) | Antipyretic analgesic containing ibuprofen | |
| US20180125792A1 (en) | Non-steroidal anti-inflammatory drugs for cough | |
| JP2001247481A (en) | Medicinal composition | |
| WO2008038423A1 (en) | Antiphlogistc and analgetic composition for oral use | |
| JP4384435B2 (en) | Sneezing suppression composition | |
| JPH083066A (en) | Therapeutic drug for cold | |
| JP2000080034A (en) | Composition for cold | |
| JP2001181190A (en) | Medicine composition | |
| WO2017100324A1 (en) | Combination therapy for treating female hypoactive sexual desire disorders | |
| US20070092583A1 (en) | Cold remedy composition comprising zinc salts | |
| JP2001261561A (en) | Drug for ameliorating nasal obstruction | |
| JP2001089375A (en) | Composition for common cold | |
| JPH11255641A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060518 |